SCHEMBL4677385

SCHEMBL4677385

NC(=O)[C@H](Cc1cccc(F)c1)NC(=O)[CH]CCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FCER2 P06734 2/20 0.45
MMP3 P08254 1/20 0.45
MMP9 P14780 1/20 0.45
GPR52 Q9Y2T5 1/20 0.44
SLC1A1 P43005 2/20 0.44
HPGDS O60760 4/20 0.43
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
CTSL P07711 1/20 0.41
TP53 P04637 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PARP1 P09874 1/20 0.41
PARP3 Q9Y6F1 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
CAPN1 P07384 1/20 0.40
CTSB P07858 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677869 0.84 HPGDS (0.48) FCER2MMP3MMP9SLC1A1HPGDS
SCHEMBL4679200 0.84 FCER2 (0.56) FCER2MMP3MMP9GPR52CTSL
SCHEMBL4679398 0.83 GPR52 (0.47) GPR52TAAR1CAPN1
SCHEMBL23356941 0.81 SLC1A1 (0.54) FCER2MMP3MMP9SLC1A1HPGDS
SCHEMBL23356943 0.81 SLC1A1 (0.54) FCER2MMP3MMP9SLC1A1HPGDS
SCHEMBL4679895 0.81 NOS2 (0.48) FCER2HPGDSCTSLPARP1PARP3
SCHEMBL4677881 0.80 FCER2 (0.52) FCER2MMP3MMP9CAPN1CTSB
SCHEMBL4680585 0.80 CTSS (0.45) FCER2MMP3MMP9SLC1A1HPGDS
SCHEMBL4683513 0.78 SLC1A1 (0.41) FCER2MMP3MMP9SLC1A1
SCHEMBL13538441 0.77 FCER2 (0.55) FCER2MMP3MMP9SLC1A1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP claimed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 FCER2 588/4885MMP3 33/4885MMP9 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.